Free Trial
→ Why Buffett and 100 members of Congress are Piling into this One Investment (From Behind the Markets) (Ad)

Ainos Q3 2024 Earnings Report

Ainos logo
$0.62 -0.01 (-1.88%)
As of 02/21/2025 03:59 PM Eastern
Earnings History

Ainos EPS Results

Actual EPS
-$0.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q3 2024
Date
11/6/2024
Time
N/A

Conference Call Resources

Ainos Earnings Headlines

Ainos granted 180-day extension to regain Nasdaq compliance
January 18, 2025 | markets.businessinsider.com
Ainos, Inc. Reports Q3 Financial Results and Strategic Developments
November 25, 2024 | tipranks.com
9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
February 22, 2025 | Wealthpin Pro (Ad)
Ainos announces IRB approval for Sjogren’s Syndrome clinical study
November 11, 2024 | markets.businessinsider.com
Ainos files complaints over concerns about unsual trading activity
November 8, 2024 | markets.businessinsider.com
Ainos, Inc.: Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024 | finanznachrichten.de
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD), a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

View Ainos Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles